Could This FDA Approval Be a Boost for Merck?

Could This FDA Approval Be a Boost for Merck?

Source: 
Motley Fool
snippet: 
  • Keytruda now has access to another patient pool of several thousand patients.
  • The indication could generate $200 million in annual revenue for Merck.
  • Merck looks like a stock that offers something for everyone to like.